Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBPNASDAQ:HILSNASDAQ:IOBTNASDAQ:IRWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$8.83-3.7%$7.20$4.64▼$61.90$108.05M3.11350,037 shs97,933 shsHILSHillstream BioPharma$1.37-12.7%$1.37$0.19▼$2.65$24.12M3.081.39 million shs111,547 shsIOBTIO Biotech$1.35-10.0%$1.09$0.66▼$1.73$88.94M0.36281,548 shs383,059 shsIRWDIronwood Pharmaceuticals$0.62-7.2%$0.75$0.53▼$7.11$100.33M0.242.61 million shs1.94 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals+2.23%+4.20%+26.31%+35.05%-82.11%HILSHillstream BioPharma-1.88%-0.39%+3.97%+8.28%-48.93%IOBTIO Biotech0.00%0.00%+50.00%+70.69%+17.19%IRWDIronwood Pharmaceuticals-7.39%+17.06%-2.31%-55.14%-89.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals4.0795 of 5 stars3.61.00.04.73.62.50.0HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AIOBTIO Biotech4.0264 of 5 stars3.75.00.00.03.62.51.3IRWDIronwood Pharmaceuticals4.5132 of 5 stars4.13.00.03.42.50.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$50.88476.16% UpsideHILSHillstream BioPharma 0.00N/AN/AN/AIOBTIO Biotech 3.33Buy$9.33591.36% UpsideIRWDIronwood Pharmaceuticals 2.13Hold$4.78671.51% UpsideCurrent Analyst Ratings BreakdownLatest HILS, CRBP, IOBT, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.004/16/2025IRWDIronwood PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025IRWDIronwood PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.004/15/2025IRWDIronwood PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $0.704/14/2025IRWDIronwood PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.004/14/2025IRWDIronwood PharmaceuticalsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/1/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A($1.56) per shareN/AHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$2.02 per shareN/AIRWDIronwood Pharmaceuticals$317.68M0.32N/AN/A($2.21) per share-0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$44.60M-$4.22N/AN/AN/AN/A-42.28%-32.92%8/5/2025 (Estimated)HILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/AIOBTIO Biotech-$86.08M-$1.37N/AN/AN/AN/A-86.56%-75.24%8/12/2025 (Estimated)IRWDIronwood Pharmaceuticals-$1.00B-$0.20N/A2.48N/A-0.65%-0.96%0.74%8/6/2025 (Estimated)Latest HILS, CRBP, IOBT, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A13.8413.84HILSHillstream BioPharmaN/A3.013.01IOBTIO BiotechN/A5.375.37IRWDIronwood PharmaceuticalsN/A3.623.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%HILSHillstream BioPharma13.36%IOBTIO Biotech54.76%IRWDIronwood PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.60%HILSHillstream BioPharma30.24%IOBTIO Biotech4.80%IRWDIronwood Pharmaceuticals12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.24 million11.69 millionOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableIOBTIO Biotech3065.88 million64.37 millionNot OptionableIRWDIronwood Pharmaceuticals220161.82 million139.38 millionOptionableHILS, CRBP, IOBT, and IRWD HeadlinesRecent News About These CompaniesWhy Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?June 6, 2025 | zacks.com426,138 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by Universal Beteiligungs und Servicegesellschaft mbHJune 3, 2025 | marketbeat.comAnalysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $4.78June 3, 2025 | americanbankingnews.comZacks Research Has Bearish Estimate for IRWD Q2 EarningsJune 3, 2025 | americanbankingnews.comZacks Research Issues Pessimistic Estimate for IRWD EarningsJune 2, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Hold" by BrokeragesJune 1, 2025 | marketbeat.comZacks Research Issues Optimistic Outlook for IRWD EarningsMay 31, 2025 | marketbeat.comMan Group plc Has $1.57 Million Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)May 26, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Bought by Deutsche Bank AGMay 20, 2025 | marketbeat.comWhy Ironwood Pharmaceuticals, Inc.’s (IRWD) Stock Is Down 5.28%May 15, 2025 | aaii.comJacobs Levy Equity Management Inc. Reduces Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)May 15, 2025 | marketbeat.comLeerink Partnrs Has Bullish Outlook for IRWD Q2 EarningsMay 13, 2025 | marketbeat.comWhy Ironwood Pharmaceuticals, Inc.’s (IRWD) Stock Is Up 5.49%May 10, 2025 | aaii.comPacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc.May 8, 2025 | gurufocus.comPacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc.May 8, 2025 | gurufocus.comIRWD Stock Down 15% as Q1 Earnings & Revenues Miss EstimatesMay 8, 2025 | zacks.comIronwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2025 | zacks.comIronwood Pharmaceuticals Reports First Quarter 2025 ResultsMay 7, 2025 | businesswire.comAnalysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out forMay 1, 2025 | zacks.comIronwood Pharmaceuticals to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comIronwood Raises 2025 Adj. EBITDA OutlookApril 26, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHILS, CRBP, IOBT, and IRWD Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$8.83 -0.34 (-3.71%) Closing price 04:00 PM EasternExtended Trading$8.84 +0.01 (+0.11%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Hillstream BioPharma NASDAQ:HILS$1.37 -0.20 (-12.74%) As of 06/12/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.IO Biotech NASDAQ:IOBT$1.35 -0.15 (-10.00%) Closing price 04:00 PM EasternExtended Trading$1.34 -0.01 (-0.74%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Ironwood Pharmaceuticals NASDAQ:IRWD$0.62 -0.05 (-7.24%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.06 (+10.16%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
